– UK, Slough – Indivior PLC (LON: INDV) announced the appointment of current Non-Executive Director Dr. David Wheadon (M.D.) as Chair of the Board of Directors with immediate effect.
“I am delighted to announce David’s appointment as Chair of the Board and am confident he will bring strong leadership to the role, leveraging his track record across specialty pharma and beyond. David has already established himself as a valued member of the Board and we look forward to benefitting from his continued insights and deep strategic and operational experience as we work together to deliver value to all Indivior stakeholders,” said Lead Independent Director, Juliet Thompson.
About Dr. David Wheadon
Dr. David Wheadon joined the Board as a Non-Executive Director in June 2024 and served as SVP of global regulatory affairs, patient safety, and quality assurance at AstraZeneca Plc from December 2014 to July 2019. Before that, he was EVP of research and advocacy at Juvenile Diabetes Research Foundation International Inc., from May 2013 to December 2014, and SVP of scientific and regulatory affairs at Pharmaceutical Research and Manufacturers of America (PhRMA), from January 2009 to May 2013. Before that, he served as VP of global pharmaceutical regulatory and medical science, and group VP of global pharmaceutical regulatory affairs at Abbott Laboratories from 2005 to 2009 and held senior regulatory and clinical development leadership positions at GlaxoSmithKline Plc and Eli Lilly and Company.
Dr. David Wheadon received his M.D. from Johns Hopkins University School of Medicine and an A.B. in Biology from Harvard University. He completed his postdoctoral training in Psychiatry at Tufts/New England Medical Center in Boston, Massachusetts.
Dr. David Wheadon is a Non-Executive Independent Director of Sotera Health Company and Vaxart, Inc. He also serves as a member of the Board of Trustees of Mount Sinai Health System.
Dr. David Wheadon commented; “It is an honor to become Chair of the Board of Indivior. This is a great company which is unwavering in its mission to help change patients’ lives by pioneering life-transforming treatment for opioid use disorder. I am very proud to be appointed to lead the Board and support that mission. I look forward to working closely with the Board and management team to leverage Indivior’s deep expertise, long track record and strong culture. As a Board, we are determined to help realize the Company’s great potential and deliver value for shareholders and our wider stakeholders.”
About Indivior
Indivior is a global pharmaceutical company working to help change patients’ lives by developing medicines to treat substance use disorders (SUD). Our vision is that all patients around the world will have access to evidence-based treatment for the chronic conditions and co-occurring disorders of SUD. Indivior is dedicated to transforming SUD from a global human crisis to a recognized and treated chronic disease. Building on its global portfolio of OUD treatments, Indivior has a pipeline of product candidates designed to expand on its heritage in this category. Headquartered in the United States in Richmond, VA, Indivior employs over 1,000 individuals globally and its portfolio of products is available in over 30 countries worldwide.
For more: https://www.indivior.com/en
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.